卡莫氟

C₁₁H₁₆FN₃O₃

257.26

MFCD00866284

329774890

NA.77

Carmofur has been used as an inhibitor of acid ceramidase to study its effects on glucosylsphingosine (GlcSph) production in human embryonic kidney 293T (HEK293T) cells. It has also been used as an inhibitor of acid ceramidase to study its effects on acid‐mediated hydrolysis of ceramide which kicks-in consumption and the generation of sphingosine .

Carmofur is a derivative of fluorouracil, an antimetabolite used as an antineoplastic agent.
Carmofur acts as an inhibitor of fatty acid amide hydrolase (FAAH), N-acylethanolamine acid amidase (NAAA) and acid ceramidase (ASAH1). Carmofur has a therapeutic activity against colorectal and cervical cancer. It can inhibit the severe acute respiratory syndrome (SARS)-CoV-2 main protease (M^pro) in vitro.

100

≥98% (HPLC)

powder

white to off-white

DMSO: >15 mg/mL

2-8℃

CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O

1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)

AOCCBINRVIKJHY-UHFFFAOYSA-N

10, 50 mg in glass bottle

GHS06,GHS08

Danger

H301 - H361

P201 - P301 + P310 + P330

Acute Tox. 3 Oral - Repr. 2

6.1B - Non-combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK 3